Compare ASLE & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASLE | CRDL |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.5M | 226.6M |
| IPO Year | 2018 | 2017 |
| Metric | ASLE | CRDL |
|---|---|---|
| Price | $4.76 | $1.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $7.25 | ★ $8.42 |
| AVG Volume (30 Days) | 473.7K | ★ 1.5M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $335,286,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.71 | $0.88 |
| 52 Week High | $8.04 | $2.34 |
| Indicator | ASLE | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 30.77 | 22.26 |
| Support Level | $4.71 | $0.96 |
| Resistance Level | $5.90 | $1.35 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 3.59 | 1.34 |
AerSale Corp offers full-service support to owners and operators of mid-life commercial aircraft. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing various maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. The company has two reportable segments: Asset Management Solutions and TechOps. Maximum revenue is generated from the Asset Management Solutions segment, which comprises activities to extract value from strategic asset acquisitions through leasing, trading, or disassembling for product sales. Geographically, the company derives maximum revenue from its domestic market.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.